卵巢癌的降风险手术：300 例手术的结果表明腹膜原发风险较低。
Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.
机构信息
University of Manchester and Central Manchester and Manchester Children's University Hospitals NHS Trust, St Mary's Hospital, UK.
出版信息
Eur J Hum Genet. 2009 Nov;17(11):1381-5. doi: 10.1038/ejhg.2009.60. Epub 2009 Apr 15.
Abstract
Risk-reducing salpingo-oophorectomy is currently advocated for the reduction of both breast and ovarian cancer risk in BRCA1/2 carriers, but residual risk of peritoneal primary cancer remains a concern. A sequential series of women attending a single institution for ovarian risk management underwent either risk-reducing surgery or screening. A person-years at risk analysis was used to compare observed versus expected cancers. In total, 300 women underwent risk-reducing salpingo-oophorectomy, including 160 BRCA1/2 mutation carriers. Three occult ovarian cancers were detected at surgery. There have been 2400.4 years of follow-up and 15.79 expected cancers. No peritoneal cancers have occurred. Amongst 503 women controls with 3444.3 years of follow-up, 15.93 ovarian cancers were expected and 17 were found. There were six ovarian cancer-related deaths in the control group compared with one in the surgery group. Risk-reducing salpingo-oophorectomy in a single institution has so far avoided peritoneal cancer incidence.
摘要
预防性输卵管卵巢切除术目前被提倡用于降低 BRCA1/2 携带者的乳腺癌和卵巢癌风险，但仍存在腹膜原发性癌症的残余风险。为了进行卵巢风险管理，一系列女性在一家机构接受了预防性手术或筛查。采用个体风险年分析比较观察到的癌症与预期癌症。共有 300 名女性接受了预防性输卵管卵巢切除术，其中包括 160 名 BRCA1/2 基因突变携带者。手术中发现了 3 例隐匿性卵巢癌。目前已经随访了 2400.4 年，预计有 15.79 例癌症发生。未发生腹膜癌。在 503 名对照组女性中，随访时间为 3444.3 年，预计有 15.93 例卵巢癌发生，实际发现了 17 例。对照组中有 6 例与卵巢癌相关的死亡病例，而手术组中只有 1 例。单机构的预防性输卵管卵巢切除术迄今已避免了腹膜癌的发生。
相似文献
1
Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.
Eur J Hum Genet. 2009 Nov;17(11):1381-5. doi: 10.1038/ejhg.2009.60. Epub 2009 Apr 15.
2
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20.
3
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
JAMA. 2006 Jul 12;296(2):185-92. doi: 10.1001/jama.296.2.185.
4
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Am J Obstet Gynecol. 2006 Jun;194(6):1702-9. doi: 10.1016/j.ajog.2006.03.006.
5
Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.
6
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Br J Cancer. 2004 Apr 19;90(8):1492-7. doi: 10.1038/sj.bjc.6601692.
7
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.
8
Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.
9
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8. doi: 10.1093/jnci/95.14.1072.
10
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Gynecol Oncol. 2020 May;157(2):514-520. doi: 10.1016/j.ygyno.2020.02.006. Epub 2020 Mar 19.
引用本文的文献
1
Prevention of Epithelial Ovarian Cancer.
Cold Spring Harb Perspect Med. 2023 Aug 1;13(8):a038216. doi: 10.1101/cshperspect.a038216.
2
Hereditary Gynecologic Cancer Syndromes - A Narrative Review.
Onco Targets Ther. 2022 Apr 8;15:381-405. doi: 10.2147/OTT.S353054. eCollection 2022.
3
Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.
4
The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Radiol Oncol. 2020 May 28;54(2):180-186. doi: 10.2478/raon-2020-0020.
5
Peritoneal cancer after bilateral mastectomy, hysterectomy, and bilateral salpingo-oophorectomy with a poor prognosis: A case report and review of the literature.
World J Clin Cases. 2019 Nov 26;7(22):3872-3880. doi: 10.12998/wjcc.v7.i22.3872.
6
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):927-948. doi: 10.1055/a-0646-4522. Epub 2018 Oct 19.
7
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
8
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.
Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.
9
Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.
Oncol Lett. 2016 Nov;12(5):3101-3114. doi: 10.3892/ol.2016.5058. Epub 2016 Aug 29.
10
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.
本文引用的文献
1
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.
2
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
J Med Genet. 2009 Sep;46(9):593-7. doi: 10.1136/jmg.2008.058248. Epub 2008 Apr 15.
3
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11.
4
Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers.
Eur J Cancer. 2007 Jul;43(11):1713-7. doi: 10.1016/j.ejca.2007.04.023. Epub 2007 Jun 15.
5
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
Br J Cancer. 2007 May 7;96(9):1335-42. doi: 10.1038/sj.bjc.6603725. Epub 2007 Apr 10.
6
Update on ovarian cancer screening.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):22-6. doi: 10.1097/GCO.0b013e328011ec99.
7
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706. doi: 10.1093/jnci/djj465.
8
Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:54-9. doi: 10.1111/j.1525-1438.2006.00480.x.
9
Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
J Clin Oncol. 2005 Aug 20;23(24):5588-96. doi: 10.1200/JCO.2005.05.097.
10
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
J Clin Oncol. 2005 Jan 1;23(1):127-32. doi: 10.1200/JCO.2005.04.109.
Zotero 插件